Detalhe da pesquisa
1.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 419-432, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31020608
2.
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Cancer
; 122(23): 3641-3649, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27648727
3.
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Clin Cancer Res
; 21(8): 1888-95, 2015 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25652454